CORT shares have a strong debt-to-equity ratio but their quick ratio which reads 5.40 is strong and might cause problems for them later in the future.

Even though there was a rise of +50.70% in revenue, the company failed to succeed in outperforming the industry average of 4.36%. For the most recent quarter, the net income has jumped by +29.00%. This strength in their income has affected them and thus increased their earnings to $23.03 M. The 50.70% yoy growth of CORT’s revenue has gone up that of the industry average by -32.52%. For the past 12 months, Corcept Therapeutics Incorporated revenue has gone up by 83.22%. The sustained growth in their revenue has helped boost their earnings per share.

Corcept Therapeutics Incorporated (CORT) has seen their earnings per share increased to $0.14 during the last quarter in comparison to the same quarter last year. They have recorded a -1.42% declining earnings per share earnings. They have recorded a -1.42% declining earnings per share earnings. Analysts expect increase in earnings is also on the cards next quarter with an average estimate at $0.18. In the fiscal year 2018, Corcept Therapeutics Incorporated overcame its bottom line by hitting earning $1.04 per share compared to the $0.07 in 2017.

The 12-month return on equity has significantly fallen to 106.96 in comparison to the same data for other companies in the same industry. This shows that there is a major weakness within the organization over the past one year. Comparing them to other companies in the industry and the overall Healthcare sector, the industry average is 15.85 while 15.29 is of the sector.

CORT total operating cash flow had jumped to $44.51 billion compared to $15.21 billion in the same quarter last year. Also, looking at the price to cash flow of the company and the industry average, the 8.50 ratio of the stock is lower than the industry’s 21.70.

Corcept Therapeutics Incorporated (NASDAQ:CORT) has a price-to-earnings ratio of 9.40 which is lower than the 29.45 industry average at the moment. In addition to their unfavorable P/E ratio, Corcept Therapeutics Incorporated has maintained a gross margin of 97.98. This shows whether the company has what it takes to effectively turn the revenue into profit.

The company’s ROA is 90.13 when compared to 11.53 for the stocks operating in the same industry. This can be attributed to the strength recorded in the net income produced by total assets. Comparing it to other companies in the sector, Corcept Therapeutics Incorporated ROE is above 15.29 that of both the sector average.

The operating profit margin for Corcept Therapeutics Incorporated (CORT) is 36.30%, a figure which is considered to be strong. It has gone 8.35 from the -2.91 over the past 5 years. In addition to this, their operating margin is 27.95 higher than the industry average.

The net profit margin which stood at 26.45 on average in the past 5 years has jumped to 77.82 in the last 12 months. Added to that, this ratio has surpassed the industry net margin that stands at 5.44.

Analysts meanwhile rate Corcept Therapeutics Incorporated (NASDAQ:CORT) as a buy. Still some above discussed indicators of the $1.59B company show strength while others show weakness. There is little evidence at the moment to justify the expectation of the CORT shares to either perform positively or negatively when compared to other stocks. The primary strengths of Corcept Therapeutics Incorporated can be witnessed in its increased revenue, growing earnings per share, higher return on equity, increased operating cash and high net margin. Subsequently, financial analysis have also identified some weak areas that includes high debt, relatively high P/E ratio, lower return on assets and low net margin.